Review





Similar Products

96
Miltenyi Biotec human b cell isolation kit ii
Human B Cell Isolation Kit Ii, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/B+Cell+Isolation+Kit+II%2C+human/pm42887576-65-20-35
Average 96 stars, based on 1 article reviews
human b cell isolation kit ii - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Elabscience Biotechnology human hepatitis b surface antigen hbsag elisa kit
Human Hepatitis B Surface Antigen Hbsag Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/Human+HBsAg+(Hepatitis+B+surface+antigen)+ELISA+Kit/pm42913940-101-11-22
Average 93 stars, based on 1 article reviews
human hepatitis b surface antigen hbsag elisa kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Sino Biological biotinylated human tnf α
Biotinylated Human Tnf α, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/Human+TNF-alpha+%2F+TNFA+Protein%2C+Biotinylated/pm42900781-262-0-5
Average 94 stars, based on 1 article reviews
biotinylated human tnf α - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Elabscience Biotechnology human granzyme b elisa kit
HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Human Granzyme B Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/Human+GzmB+(Granzyme+B)+ELISA+Kit/pmc13682500-84-41-47
Average 94 stars, based on 1 article reviews
human granzyme b elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec naïve b cell isolation kit ii human
HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Naïve B Cell Isolation Kit Ii Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/B+Cell+Isolation+Kit+II%2C+human/pmc13673512-182-11-18
Average 96 stars, based on 1 article reviews
naïve b cell isolation kit ii human - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC cd19 human b cell precursor 428 leukemia line nalm6
HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Cd19 Human B Cell Precursor 428 Leukemia Line Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/NALM6%2C+clone+G5/pm42888846-174-1-36
Average 96 stars, based on 1 article reviews
cd19 human b cell precursor 428 leukemia line nalm6 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Elabscience Biotechnology human bcl 2
HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Human Bcl 2, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/Human+Bcl-2+(B-cell+Leukemia%2FLymphoma+2)+ELISA+Kit/pm42875898-96-23-30
Average 93 stars, based on 1 article reviews
human bcl 2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Sino Biological plate
HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Plate, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/Human+EGFR+%2F+HER1+%2F+ErbB1+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/pmc13669479-415-2-12
Average 94 stars, based on 1 article reviews
plate - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
OriGene ccr2 variant b
Kaplan-Meier analysis of overall survival (OS) stratified by <t>CCR2</t> expression levels across Group 3 MB at all ages in the Cavalli (A) and Williamson (B) datasets. Kaplan-Meier analysis of OS, stratified by CCR2 expression levels, across Group 3 MB int the 4 - 10 years old age range in the Cavalli (C) and Williamson (D) datasets. Shaded areas represent 95% confidence intervals and statistical significance was determined using the two-tailed log-rank test. ( E ) In the Cavalli dataset CCR2 is highly expressed in metastatic (M1) cases compared to non-metastatic (M0) cases (p=0.0483). Statistical significance was determined using the non-parametric Mann-Whitney test. ( F ) Semi-quantitative analysis of CCR2 protein expression in a cohort of 11 paired primary and metastatic/recurrent MB samples (p<0.0001). Statistical significance was determined using the Chi-Square tests. ( G ) Representative IHC images illustrating the four-tier scoring system used to evaluate staining: level I (low frequency/low intensity), level II (low frequency/high intensity), level III (high frequency/low intensity), and level IV (high frequency/high intensity). Scale bars represent 100 μm. Significance levels: *p<0.05, **p<0.01; ****p<0.0001; ns, not significant.
Ccr2 Variant B, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+b/CCR2+(NM_001123396)+Human+Tagged+ORF+Clone/bio_rxiv__64898__2026__10__11__757412-65-9-12
Average 94 stars, based on 1 article reviews
ccr2 variant b - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

doi: 10.1002/jbt.71127

Figure Lengend Snippet: HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

Techniques: Migration, Analysis, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Flow Cytometry, Transwell Assay, Comparison, X-Ray Photoelectron Spectroscopy

TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

doi: 10.1002/jbt.71127

Figure Lengend Snippet: TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

Techniques: Enzyme-linked Immunosorbent Assay, Analysis, Concentration Assay, Transwell Migration Assay, Migration, Comparison

The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

doi: 10.1002/jbt.71127

Figure Lengend Snippet: The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

Techniques: Cell Function Assay, Flow Cytometry, Analysis, Enzyme-linked Immunosorbent Assay, Comparison

Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

doi: 10.1002/jbt.71127

Figure Lengend Snippet: Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

Techniques: Flow Cytometry, Analysis, Immune Cell, Tissue, Enzyme-linked Immunosorbent Assay, Comparison

Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

doi: 10.1002/jbt.71127

Figure Lengend Snippet: Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

Techniques: Biomarker Discovery, In Situ, Immunohistochemical staining, Staining, Analysis, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison

Kaplan-Meier analysis of overall survival (OS) stratified by CCR2 expression levels across Group 3 MB at all ages in the Cavalli (A) and Williamson (B) datasets. Kaplan-Meier analysis of OS, stratified by CCR2 expression levels, across Group 3 MB int the 4 - 10 years old age range in the Cavalli (C) and Williamson (D) datasets. Shaded areas represent 95% confidence intervals and statistical significance was determined using the two-tailed log-rank test. ( E ) In the Cavalli dataset CCR2 is highly expressed in metastatic (M1) cases compared to non-metastatic (M0) cases (p=0.0483). Statistical significance was determined using the non-parametric Mann-Whitney test. ( F ) Semi-quantitative analysis of CCR2 protein expression in a cohort of 11 paired primary and metastatic/recurrent MB samples (p<0.0001). Statistical significance was determined using the Chi-Square tests. ( G ) Representative IHC images illustrating the four-tier scoring system used to evaluate staining: level I (low frequency/low intensity), level II (low frequency/high intensity), level III (high frequency/low intensity), and level IV (high frequency/high intensity). Scale bars represent 100 μm. Significance levels: *p<0.05, **p<0.01; ****p<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: Kaplan-Meier analysis of overall survival (OS) stratified by CCR2 expression levels across Group 3 MB at all ages in the Cavalli (A) and Williamson (B) datasets. Kaplan-Meier analysis of OS, stratified by CCR2 expression levels, across Group 3 MB int the 4 - 10 years old age range in the Cavalli (C) and Williamson (D) datasets. Shaded areas represent 95% confidence intervals and statistical significance was determined using the two-tailed log-rank test. ( E ) In the Cavalli dataset CCR2 is highly expressed in metastatic (M1) cases compared to non-metastatic (M0) cases (p=0.0483). Statistical significance was determined using the non-parametric Mann-Whitney test. ( F ) Semi-quantitative analysis of CCR2 protein expression in a cohort of 11 paired primary and metastatic/recurrent MB samples (p<0.0001). Statistical significance was determined using the Chi-Square tests. ( G ) Representative IHC images illustrating the four-tier scoring system used to evaluate staining: level I (low frequency/low intensity), level II (low frequency/high intensity), level III (high frequency/low intensity), and level IV (high frequency/high intensity). Scale bars represent 100 μm. Significance levels: *p<0.05, **p<0.01; ****p<0.0001; ns, not significant.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Analysis, Expressing, Two Tailed Test, MANN-WHITNEY, Chi-Square, Staining

( A ) CCR2 gene expression across Group3 MB subtypes (Kruskal-Wallis p=0.19). Kaplan-Meier analysis of survival stratified according to CCR2 gene expression across Group 3 MB ( B ) subtype α, ( C ) subtype β and ( D ) subtype γ. Shaded areas in the Kaplan-Meier plots represent 95% confidence intervals, and vertical tick marks indicate censored data. Statistical analysis was performed using Kruskal-Wallis testing and Log-rank Mantel-Cox test.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) CCR2 gene expression across Group3 MB subtypes (Kruskal-Wallis p=0.19). Kaplan-Meier analysis of survival stratified according to CCR2 gene expression across Group 3 MB ( B ) subtype α, ( C ) subtype β and ( D ) subtype γ. Shaded areas in the Kaplan-Meier plots represent 95% confidence intervals, and vertical tick marks indicate censored data. Statistical analysis was performed using Kruskal-Wallis testing and Log-rank Mantel-Cox test.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Gene Expression, Analysis

( A ) Representative flow cytometry histograms for ONS76 cells showing the distribution of CCR2-PE staining. The stable overexpression (OE-CCR2) line exhibited a marked shift in median fluorescence intensity (MFI = 4525) compared to the vector control (MFI = 212) and unstained control (MFI = 48). ( B ) Quantification of the percentage of CCR2-positive ONS76 cells, demonstrating near-total surface expression in the OE-CCR2 population compared to controls. ( C ) Representative histograms for UW228 cells showing a similar substantial shift in fluorescence intensity in OE-CCR2 cells (MFI = 3397) relative to vector control (MFI = 63) and unstained control (MFI = 23) populations. ( D ) Quantification of the percentage of CCR2-positive UW228 cells, confirming high-efficiency surface expression following stable transfection ( E ) Proliferation kinetics of UW228 cells with and without stimulation with 50 ng/mL CCL2 (p<0.05 at 72h; p<0.01 at 96h). ( F ) Migration assay in UW228 OE-CCR2 cells at 36 hours. Data represents the results of three independent experiments performed in triplicate. Values are expressed as the median with the interquartile range. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Representative flow cytometry histograms for ONS76 cells showing the distribution of CCR2-PE staining. The stable overexpression (OE-CCR2) line exhibited a marked shift in median fluorescence intensity (MFI = 4525) compared to the vector control (MFI = 212) and unstained control (MFI = 48). ( B ) Quantification of the percentage of CCR2-positive ONS76 cells, demonstrating near-total surface expression in the OE-CCR2 population compared to controls. ( C ) Representative histograms for UW228 cells showing a similar substantial shift in fluorescence intensity in OE-CCR2 cells (MFI = 3397) relative to vector control (MFI = 63) and unstained control (MFI = 23) populations. ( D ) Quantification of the percentage of CCR2-positive UW228 cells, confirming high-efficiency surface expression following stable transfection ( E ) Proliferation kinetics of UW228 cells with and without stimulation with 50 ng/mL CCL2 (p<0.05 at 72h; p<0.01 at 96h). ( F ) Migration assay in UW228 OE-CCR2 cells at 36 hours. Data represents the results of three independent experiments performed in triplicate. Values are expressed as the median with the interquartile range. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Flow Cytometry, Staining, Over Expression, Fluorescence, Plasmid Preparation, Control, Expressing, Stable Transfection, Migration, MANN-WHITNEY

( A ) Proliferation kinetics (fold change to 0h) of ONS76 cells measured by MTS assay over 96 hours. Overexpression of CCR2 alone did not affect ONS76 cell proliferation. However, upon stimulation with 50ng/mL of CCL2, ONS76 OE-CCR2 cells exhibited a significant increase in proliferation compared to control cells and non-stimulated ONS76 OE-CCR2 (p<0.01 for all time points 24–96h). ( B ) Migration of ONS76 OE-CCR2 cells assessed by Boyden chamber assay at 16 hours. CCL2 stimulation significantly increased the migratory capacity of OE-CCR2 cells compared to unstimulated OE-CCR2 cells (p<0.0001). ( C-E ) Analysis of ERK and AKT signaling pathways in ONS76 OE-CCR2 following stimulation with 50 ng/mL of recombinant CCL2. ( C ) Representative immunoblots showing levels of phosphorylated AKT (p-AKT), total AKT, phosphorylated ERK (p-ERK), total ERK, and Actin (loading control) at various time intervals (1, 5, 15, 30, and 60 minutes) post-stimulation compared to non-stimulated (NS) cells. ( D ) Densitometry analysis of p-ERK relative to total ERK levels across three independent experiments. Stimulation with CCL2 revealed a visible tendency towards increased ERK activation, particularly at the 1-minute and 5-minute time points. ( E ) Densitometry analysis of p-AKT relative to total AKT levels. In contrast to ERK, no consistent trend in activation of the AKT pathway was observed following CCL2 treatment in these cells. Data represents results from three independent experiments and is expressed as median with interquartile range or as fold change in arbitrary units (AU). Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: **p<0.01, ****p<0.0001.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Proliferation kinetics (fold change to 0h) of ONS76 cells measured by MTS assay over 96 hours. Overexpression of CCR2 alone did not affect ONS76 cell proliferation. However, upon stimulation with 50ng/mL of CCL2, ONS76 OE-CCR2 cells exhibited a significant increase in proliferation compared to control cells and non-stimulated ONS76 OE-CCR2 (p<0.01 for all time points 24–96h). ( B ) Migration of ONS76 OE-CCR2 cells assessed by Boyden chamber assay at 16 hours. CCL2 stimulation significantly increased the migratory capacity of OE-CCR2 cells compared to unstimulated OE-CCR2 cells (p<0.0001). ( C-E ) Analysis of ERK and AKT signaling pathways in ONS76 OE-CCR2 following stimulation with 50 ng/mL of recombinant CCL2. ( C ) Representative immunoblots showing levels of phosphorylated AKT (p-AKT), total AKT, phosphorylated ERK (p-ERK), total ERK, and Actin (loading control) at various time intervals (1, 5, 15, 30, and 60 minutes) post-stimulation compared to non-stimulated (NS) cells. ( D ) Densitometry analysis of p-ERK relative to total ERK levels across three independent experiments. Stimulation with CCL2 revealed a visible tendency towards increased ERK activation, particularly at the 1-minute and 5-minute time points. ( E ) Densitometry analysis of p-AKT relative to total AKT levels. In contrast to ERK, no consistent trend in activation of the AKT pathway was observed following CCL2 treatment in these cells. Data represents results from three independent experiments and is expressed as median with interquartile range or as fold change in arbitrary units (AU). Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: **p<0.01, ****p<0.0001.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: MTS Assay, Over Expression, Control, Migration, Boyden Chamber Assay, Analysis, Protein-Protein interactions, Recombinant, Western Blot, Activation Assay, MANN-WHITNEY

( A ) Schematic representation of the orthotopic injection of ONS76 cells in NSG mice and experimental outline. ( B ) At 25 days post injection semi-quantitative scoring revealed higher invasion of the brain in mice injected with ONS76 OE-CCR2 cells compared to the control group. Histopathological scoring of invasion: Neg – no invasion; Low – mild invasion; High – marked brain invasion by cancer cells. ( C ) Representative images of brain invasion in both groups of mice. Arrows depict invasion foci . Scale bar: 250μm. ( D ) Semi-quantitative scoring did not reveal differences in dissemination between the two groups. Histopathological scoring of dissemination: Neg – no dissemination; Low – mild dissemination; High – marked dissemination in the leptomeninges by cancer cells. ( E ) Representative images of brain dissemination in both groups. Arrows depict dissemination areas. Scale bar: 500μm ( F ) Survival analysis revealed that mice injected with ONS76 OE-CCR2 cells (n=8) have decreased survival when compared to control mice (n=10) (p=0.0003). Data is expressed as percentage. Statistical significance was determined using the Ordinal Logistics Regression and Log-rank Mantel-Cox tests. Significance levels: *p<0.05, ns – not significant.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Schematic representation of the orthotopic injection of ONS76 cells in NSG mice and experimental outline. ( B ) At 25 days post injection semi-quantitative scoring revealed higher invasion of the brain in mice injected with ONS76 OE-CCR2 cells compared to the control group. Histopathological scoring of invasion: Neg – no invasion; Low – mild invasion; High – marked brain invasion by cancer cells. ( C ) Representative images of brain invasion in both groups of mice. Arrows depict invasion foci . Scale bar: 250μm. ( D ) Semi-quantitative scoring did not reveal differences in dissemination between the two groups. Histopathological scoring of dissemination: Neg – no dissemination; Low – mild dissemination; High – marked dissemination in the leptomeninges by cancer cells. ( E ) Representative images of brain dissemination in both groups. Arrows depict dissemination areas. Scale bar: 500μm ( F ) Survival analysis revealed that mice injected with ONS76 OE-CCR2 cells (n=8) have decreased survival when compared to control mice (n=10) (p=0.0003). Data is expressed as percentage. Statistical significance was determined using the Ordinal Logistics Regression and Log-rank Mantel-Cox tests. Significance levels: *p<0.05, ns – not significant.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Injection, Control, Analysis

( A ) Histopathological analysis showed that the incidence of spinal cord metastases is similar between ONS76 control (1 out of 10) mice and ONS76 OE-CCR2 animals (1 out of 8); (B) Representative images of the spinal cord of animals injected with these cells. Arrows depict metastases foci. Scale bar: 100μm. Data are expressed as percentage. Statistical significance was determined using the Ordinal Logistics Regression test. Significance levels: ns – not significant.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Histopathological analysis showed that the incidence of spinal cord metastases is similar between ONS76 control (1 out of 10) mice and ONS76 OE-CCR2 animals (1 out of 8); (B) Representative images of the spinal cord of animals injected with these cells. Arrows depict metastases foci. Scale bar: 100μm. Data are expressed as percentage. Statistical significance was determined using the Ordinal Logistics Regression test. Significance levels: ns – not significant.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Histopathological Analysis, Control, Injection

( A ) Schematic representation of the in-silico drug screening approach performed to identify drugs specifically targeting CCR2. Flow cytometric evaluation of CCR2 expression in ONS76 OE-CCR2 MB cells treated with 10 µM of CVC from 24h to 96h ( B ), and representative histograms of the median fluorescence intensity (MFI) for cells treated with CVC ( C ); 50 nM of MAR from 8h to 48 hours ( D ), and representative histograms of the MFI for cells treated with MAR ( E ); and 10 nM of Romidepsin from 8h to 48 hours ( F ) and representative histograms of the MFI for cells treated with ROM ( G ). DMSO was used as a negative control across all conditions. Results reflect data from two independent experiments performed in duplicate. Quantitative data are expressed as the median with interquartile range. Statistical significance was assessed using the non-parametric Mann-Whitney test. Significance levels: *p<0.05.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Schematic representation of the in-silico drug screening approach performed to identify drugs specifically targeting CCR2. Flow cytometric evaluation of CCR2 expression in ONS76 OE-CCR2 MB cells treated with 10 µM of CVC from 24h to 96h ( B ), and representative histograms of the median fluorescence intensity (MFI) for cells treated with CVC ( C ); 50 nM of MAR from 8h to 48 hours ( D ), and representative histograms of the MFI for cells treated with MAR ( E ); and 10 nM of Romidepsin from 8h to 48 hours ( F ) and representative histograms of the MFI for cells treated with ROM ( G ). DMSO was used as a negative control across all conditions. Results reflect data from two independent experiments performed in duplicate. Quantitative data are expressed as the median with interquartile range. Statistical significance was assessed using the non-parametric Mann-Whitney test. Significance levels: *p<0.05.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: In Silico, Drug discovery, Expressing, Fluorescence, Negative Control, MANN-WHITNEY

( A ) The percentage of CCR2 positive cells was significantly reduced after incubation with 50μM of CVC, as quantified by flow cytometry. ( B ) Expression levels of CCR2 at cell surface decreased with both 10μM and 50μM of CVC. ( C ) Dose-dependent inhibition of proliferation was observed in UW228 OE-CCR2 cells. ( D ) Effect of CVC treatment over CCL2-stimulated UW-228 OE-CCR2 MB cell migration. Results from 2 independent experiments performed in duplicates. Data are expressed as median with interquartile range. Data are expressed as median with interquartile range. Statistical significance was determined using two-tailed Mann-Whitney U tests. Significance levels: *p<0.05, **p<0.01.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) The percentage of CCR2 positive cells was significantly reduced after incubation with 50μM of CVC, as quantified by flow cytometry. ( B ) Expression levels of CCR2 at cell surface decreased with both 10μM and 50μM of CVC. ( C ) Dose-dependent inhibition of proliferation was observed in UW228 OE-CCR2 cells. ( D ) Effect of CVC treatment over CCL2-stimulated UW-228 OE-CCR2 MB cell migration. Results from 2 independent experiments performed in duplicates. Data are expressed as median with interquartile range. Data are expressed as median with interquartile range. Statistical significance was determined using two-tailed Mann-Whitney U tests. Significance levels: *p<0.05, **p<0.01.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Incubation, Flow Cytometry, Expressing, Inhibition, Migration, Two Tailed Test, MANN-WHITNEY

( A ) Dose dependent inhibition of proliferation in ONS76 OE-CCR2 cells stimulated with CCL2, assessed by MTS assay. ( B ) Incubation with 50 μM of CVC significantly reduced migration in ONS76 OE-CCR2 cells compared to the DMSO control group (p=0.0293). ( C ) Representative immunoblots for phosphorylated and total AKT/ERK after treatment with 5 μM or 10 μM CVC under CCL2 stimulation. ( D-E ) Densitometry analysis showed that CVC inhibits the ERK pathway activation in response to CCL2, but has no effect on AKT signaling. Data represents the results of three independent experiments. Cell counts and densitometry are expressed as the median with interquartile range or fold change. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Dose dependent inhibition of proliferation in ONS76 OE-CCR2 cells stimulated with CCL2, assessed by MTS assay. ( B ) Incubation with 50 μM of CVC significantly reduced migration in ONS76 OE-CCR2 cells compared to the DMSO control group (p=0.0293). ( C ) Representative immunoblots for phosphorylated and total AKT/ERK after treatment with 5 μM or 10 μM CVC under CCL2 stimulation. ( D-E ) Densitometry analysis showed that CVC inhibits the ERK pathway activation in response to CCL2, but has no effect on AKT signaling. Data represents the results of three independent experiments. Cell counts and densitometry are expressed as the median with interquartile range or fold change. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Inhibition, MTS Assay, Incubation, Migration, Control, Western Blot, Analysis, Activation Assay, MANN-WHITNEY

( A ) Incubation of ONS76 OE-CCR2 cells with 50nM and 100nM of Marizomib decreased cell proliferation at 96h, as assessed by MTS assay. ( B ) Representative immunoblots of Marizomib effect on ERK and AKT activation. Densitometry analysis revealed a reduction in ERK ( C ) and AKT ( D ) activation upon treatment of CCL2-stimulated ONS76 OE-CCR2 cells. ( E ) Both 2.5nM and 5nM of Romidepsin significantly decreased proliferation after 48h. ( F ) Representative immunoblots of Marizomib effect on ERK and AKT activation. Densitometry analysis revealed no effect on ERK ( G ) or AKT ( H ) activation upon stimulation of ONS76 OE-CCR2 with CCL2. Results from 2 independent experiments performed. Data are expressed as median with interquartile range. Statistical significance was determined using two-tailed Mann-Whitney U tests. Significance levels: *p<0.05, **p<0.01.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Incubation of ONS76 OE-CCR2 cells with 50nM and 100nM of Marizomib decreased cell proliferation at 96h, as assessed by MTS assay. ( B ) Representative immunoblots of Marizomib effect on ERK and AKT activation. Densitometry analysis revealed a reduction in ERK ( C ) and AKT ( D ) activation upon treatment of CCL2-stimulated ONS76 OE-CCR2 cells. ( E ) Both 2.5nM and 5nM of Romidepsin significantly decreased proliferation after 48h. ( F ) Representative immunoblots of Marizomib effect on ERK and AKT activation. Densitometry analysis revealed no effect on ERK ( G ) or AKT ( H ) activation upon stimulation of ONS76 OE-CCR2 with CCL2. Results from 2 independent experiments performed. Data are expressed as median with interquartile range. Statistical significance was determined using two-tailed Mann-Whitney U tests. Significance levels: *p<0.05, **p<0.01.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Incubation, MTS Assay, Western Blot, Activation Assay, Analysis, Two Tailed Test, MANN-WHITNEY

ONS76 OE-CCR2 cells viability was assessed by flow cytometry, after incubation with ( A ) 5 μM and 10 μM of CVC ( B ) 50nM of Marizomib or ( C ) 10nM of Romidepsin. ( D ) UW288 OE-CCR2 cells viability was assessed by flow cytometry after incubation with 10 μM and 50μM of CVC. Results from 2 independent experiments performed in triplicates. Data expressed as median with interquartile range. Data are expressed as the fold change relative to the DMSO control, shown as the median with interquartile range. All measurements were obtained via flow cytometry. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ONS76 OE-CCR2 cells viability was assessed by flow cytometry, after incubation with ( A ) 5 μM and 10 μM of CVC ( B ) 50nM of Marizomib or ( C ) 10nM of Romidepsin. ( D ) UW288 OE-CCR2 cells viability was assessed by flow cytometry after incubation with 10 μM and 50μM of CVC. Results from 2 independent experiments performed in triplicates. Data expressed as median with interquartile range. Data are expressed as the fold change relative to the DMSO control, shown as the median with interquartile range. All measurements were obtained via flow cytometry. Statistical significance was determined using the non-parametric Mann-Whitney test. Significance levels: *p<0.05, **p<0.01.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Flow Cytometry, Incubation, Control, MANN-WHITNEY

( A ) Schematic representation of the experimental design. Mice were injected in the cerebellum with 5 × 10⁵ ONS76 OE-CCR2 cells per animal. Beginning on day 4, mice were treated with vehicle (n=15) or 30 mg/kg CVC (n=10) in cycles of 5 days ON and 2 days OFF ( B ) Average body weight variation (%) monitored every other day throughout the treatment period. ( C ) Representative whole-body bioluminescence images captured at day 24 post-injection. ( D ) Quantification of the average radiance signal (p/s/cm 2 /sr) confirmed a significant reduction in overall tumor burden in CVC-treated mice compared to vehicle controls (p=0.0315). ( E ) Semi-quantitative histopathological scoring of invasion in the brain parenchyma in CVC-treated animals. ( F ) Representative H&E-stained images of tumor invasion in both groups. Black arrows denote individual invasion foci. Scale bar: 250 μm. ( G ) Semi-quantitative analysis of tumor dissemination into the leptomeningeal compartment in mice treated with CVC relative to the vehicle cohort. ( H ) Representative images depicting areas of brain dissemination (indicated by arrows). Scale bar: 500 μm. Quantitative data in panel D are expressed as individual data points with the median and interquartile range, while scoring data in panels E and G are expressed as percentages of the respective cohorts. Statistical significance was determined using the non-parametric Mann-Whitney and the Ordinal Logistics Regression tests. Significance levels: *p<0.05.

Journal: bioRxiv

Article Title: CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

doi: 10.64898/2026.10.11.757412

Figure Lengend Snippet: ( A ) Schematic representation of the experimental design. Mice were injected in the cerebellum with 5 × 10⁵ ONS76 OE-CCR2 cells per animal. Beginning on day 4, mice were treated with vehicle (n=15) or 30 mg/kg CVC (n=10) in cycles of 5 days ON and 2 days OFF ( B ) Average body weight variation (%) monitored every other day throughout the treatment period. ( C ) Representative whole-body bioluminescence images captured at day 24 post-injection. ( D ) Quantification of the average radiance signal (p/s/cm 2 /sr) confirmed a significant reduction in overall tumor burden in CVC-treated mice compared to vehicle controls (p=0.0315). ( E ) Semi-quantitative histopathological scoring of invasion in the brain parenchyma in CVC-treated animals. ( F ) Representative H&E-stained images of tumor invasion in both groups. Black arrows denote individual invasion foci. Scale bar: 250 μm. ( G ) Semi-quantitative analysis of tumor dissemination into the leptomeningeal compartment in mice treated with CVC relative to the vehicle cohort. ( H ) Representative images depicting areas of brain dissemination (indicated by arrows). Scale bar: 500 μm. Quantitative data in panel D are expressed as individual data points with the median and interquartile range, while scoring data in panels E and G are expressed as percentages of the respective cohorts. Statistical significance was determined using the non-parametric Mann-Whitney and the Ordinal Logistics Regression tests. Significance levels: *p<0.05.

Article Snippet: A lentiviral plasmid encoding the open reading frame of CCR2 variant B (Origene, RC225538L3) was used in this process.

Techniques: Injection, Staining, Analysis, MANN-WHITNEY